What is Capricor Therapeutics Book Value per Share?
Capricor Therapeutics's book value per share for the quarter that ended in Dec. 2024 was $3.19.
During the past 12 months, Capricor Therapeutics's average Book Value Per Share Growth Rate was 339.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 35.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Capricor Therapeutics was 35.00% per year. The lowest was -132.10% per year. And the median was -46.10% per year.
During the past 13 years, the highest P/B Ratio of Capricor Therapeutics was 1486.96. The lowest was 0.82. And the median was 4.27.
Capricor Therapeutics Book Value per Share Historical Data
The historical data trend for Capricor Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Capricor Therapeutics's Book Value per Share
For the Biotechnology subindustry, Capricor Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Capricor Therapeutics (NAS:CAPR) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Capricor Therapeutics Book Value per Share Related Terms
Thank you for viewing the detailed overview of Capricor Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CAPR has been successfully added to your 